• +1-646-491-9876
    • +91-20-67278686

    Search

    Chronic Myelocytic Leukemia-Pipeline Review H1 2017

    Chronic Myelocytic Leukemia-Pipeline Review H1 2017

    • Report Code ID: RW0001834319
    • Category Pharmaceuticals
    • No. of Pages 486
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides an overview of the Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline landscape.

    Chronic myeloid leukemia (CML) , also known as chronic myelogenous leukemia, is a type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood. Risk factors for CML include high-dose radiation, age and gender. Symptoms include weakness, fatigue, night sweats, weight loss, fever, bone pain, an enlarged spleen and pain or a sense of fullness in the belly. Treatment includes radiation therapy, blood cell transplantation and chemotherapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)
    Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide
    Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,
    Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017

    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is
    Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 18Number of Products under Development by Companies, H1 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    Introduction 6
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Overview 7
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Development 8
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Therapeutics Assessment 25
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Companies Involved in Therapeutics Development 39
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Drug Profiles 71
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects 452
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products 456
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Product Development Milestones 458
    Appendix 474

    List of Tables

    Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 19
    Number of Products under Development by Companies, H1 2017 21
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 22
    Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 23
    Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 24
    Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 25
    Number of Products under Development by Universities/Institutes, H1 2017 26
    Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 28
    Products under Development by Companies, H1 2017 29
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 30
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 31
    Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 32
    Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 33
    Products under Development by Universities/Institutes, H1 2017 34
    Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 35
    Number of Products by Stage and Target, H1 2017 37
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 38
    Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 39
    Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 40
    Number of Products by Stage and Mechanism of Action, H1 2017 42
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 43
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 44
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 45
    Number of Products by Stage and Route of Administration, H1 2017 47
    Number of Products by Stage and Molecule Type, H1 2017 49
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by AbbVie Inc, H1 2017 50
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Altor BioScience Corp, H1 2017 50
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by arGEN-X BV, H1 2017 51
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017 52
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Array BioPharma Inc, H1 2017 53
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H1 2017 53
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2017 54
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2017 54
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioLineRx Ltd, H1 2017 55
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BioSight Ltd, H1 2017 55
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by BLR Bio LLC, H1 2017 56
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Boston Biomedical Inc, H1 2017 56
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2017 57
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cantargia AB, H1 2017 57
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Celgene Corp, H1 2017 58
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectar Biosciences Inc, H1 2017 58
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cellectis SA, H1 2017 59
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2017 59
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H1 2017 60
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 60
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017 61
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Eisai Co Ltd, H1 2017 61
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by EpiZyme Inc, H1 2017 62
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Galena Biopharma Inc, H1 2017 62
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Gamida Cell Ltd, H1 2017 63
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2017 63
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by GlycoMimetics Inc, H1 2017 64
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hovione FarmaCiencia SA, H1 2017 64
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Hybrigenics SA, H1 2017 65
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ilyang Pharmaceutical Co Ltd, H1 2017 65
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Immune Pharmaceuticals Inc, H1 2017 66
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Incyte Corp, H1 2017 66
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Jiangsu Hansoh Pharmaceutical Group Co Ltd, H1 2017 67
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Johnson & Johnson, H1 2017 67
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Juno Therapeutics Inc, H1 2017 68
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by JW Pharmaceutical Corp, H1 2017 68
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H1 2017 69
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 69
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Mesoblast Ltd, H1 2017 70
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017 70
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Natco Pharma Ltd, H1 2017 71
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Novartis AG, H1 2017 71
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoImmune Inc, H1 2017 72
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by OncoTherapy Science Inc, H1 2017 72
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 73
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Oribase Pharma, H1 2017 73
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pfizer Inc, H1 2017 74
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Pharma Mar SA, H1 2017 74
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by PharmaEssentia Corp, H1 2017 75
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Phylogica Ltd, H1 2017 75
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Selvita SA, H1 2017 76
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Shenogen Pharma Group Ltd, H1 2017 76
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by SignalChem Lifesciences Corp, H1 2017 77
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Stemline Therapeutics Inc, H1 2017 77
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017 78
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Synactix Pharmaceuticals Inc, H1 2017 78
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Syndax Pharmaceuticals Inc, H1 2017 79
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017 79
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017 80
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017 80
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017 81
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline by Xencor Inc, H1 2017 81
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 463
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..1) , H1 2017 464
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..2) , H1 2017 465
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Dormant Projects, H1 2017 (Contd..3) , H1 2017 466
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2017 467
    Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Discontinued Products, H1 2017 (Contd..1) , H1 2017 468

    List of Figures

    Number of Products under Development for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) , H1 2017 19
    Number of Products under Development by Companies, H1 2017 20
    Number of Products under Development by Universities/Institutes, H1 2017 26
    Number of Products by Top 10 Targets, H1 2017 36
    Number of Products by Stage and Top 10 Targets, H1 2017 36
    Number of Products by Top 10 Mechanism of Actions, H1 2017 41
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 41
    Number of Products by Top 10 Routes of Administration, H1 2017 46
    Number of Products by Stage and Top 10 Routes of Administration, H1 2017 46
    Number of Products by Top 10 Molecule Types, H1 2017 48
    Number of Products by Stage and Top 10 Molecule Types, H1 2017 48
    AbbVie Inc
    Altor BioScience Corp
    arGEN-X BV
    Ariad Pharmaceuticals Inc
    Array BioPharma Inc
    Astex Pharmaceuticals Inc
    Atara Biotherapeutics Inc
    Bio-Path Holdings Inc
    BioLineRx Ltd
    BioSight Ltd
    BLR Bio LLC
    Boston Biomedical Inc
    Bristol-Myers Squibb Company
    Cantargia AB
    Celgene Corp
    Cellectar Biosciences Inc
    Cellectis SA
    Cielo Therapeutics Inc
    Constellation Pharmaceuticals Inc
    Daiichi Sankyo Company Ltd
    Deciphera Pharmaceuticals LLC
    Eisai Co Ltd
    EpiZyme Inc
    Galena Biopharma Inc
    Gamida Cell Ltd
    GlaxoSmithKline Plc
    GlycoMimetics Inc
    Hovione FarmaCiencia SA
    Hybrigenics SA
    Ilyang Pharmaceutical Co Ltd
    Immune Pharmaceuticals Inc
    Incyte Corp
    Jiangsu Hansoh Pharmaceutical Group Co Ltd
    Johnson & Johnson
    Juno Therapeutics Inc
    JW Pharmaceutical Corp
    Karyopharm Therapeutics Inc
    Lixte Biotechnology Holdings Inc
    Mesoblast Ltd
    Millennium Pharmaceuticals Inc
    Natco Pharma Ltd
    Novartis AG
    OncoImmune Inc
    OncoTherapy Science Inc
    Ono Pharmaceutical Co Ltd
    Oribase Pharma
    Pfizer Inc
    Pharma Mar SA
    PharmaEssentia Corp
    Phylogica Ltd
    Selvita SA
    Shenogen Pharma Group Ltd
    SignalChem Lifesciences Corp
    Stemline Therapeutics Inc
    Sun Pharma Advanced Research Company Ltd
    Synactix Pharmaceuticals Inc
    Syndax Pharmaceuticals Inc
    Teva Pharmaceutical Industries Ltd
    TRACON Pharmaceuticals Inc
    Tragara Pharmaceuticals Inc
    VioQuest Pharmaceuticals Inc
    Xencor Inc

    Request for Sample

    Report Url https://www.reportsweb.com//chronic-myelocytic-leukemia-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//chronic-myelocytic-leukemia-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//chronic-myelocytic-leukemia-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments